Multiple sclerosis - natalizumab
Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis
| Guidance type: Technology appraisal |
| Date issued: August 2007 |
We will consult on our review plans for this guidance in June 2010. |
| Reference: TA127 |
SummaryNatalizumab is recommended as a possible treatment for people with rapidly evolving severe relapsing-remitting multiple sclerosis. Healthcare professionals should not stop prescribing natalizumab for people with other types of multiple sclerosis who were already taking it when the guidance was issued. These people should be able to carry on taking natalizumab until they and their doctor decide that it is the right time to stop. |
| Top |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below: |
| Top |
